Search Results

Epic Bio, a leading epigenetic editing company that plans to have its FSHD program enter the clinic this year, announced its participation in the upcoming FSHD International Research Congress being held June 13-14, 2024, in Denver, Colo.

GeneDx, a leader in delivering improved health outcomes through genomic insights, announced that it is expanding access to its rapid whole genome sequencing services in neonatal intensive care units with leading health systems through a new collaboration with Epic.

Epic Bio, a leading epigenetic editing company that plans to have its FSHD program enter the clinic this year, today announced that Amber Salzman, Ph.D., chief executive officer, participated in a fireside chat at the Canaccord Genuity - Genetic Medicine for Generalists Fireside Chat today.

Epic Bio, a leading epigenetic editing company that plans to dose its first patients later this year, today announced that Amber Salzman, Ph.D., chief executive officer, will participate in a fireside chat at the Cantor Virtual Muscular Dystrophy Symposium at 9:40 a.m. PT, Tuesday, April 2, 2024.

Epic Bio, a leading epigenetic editing company that plans to dose its first patients later this year, today announced that Amber Salzman, Ph.D., chief executive officer, will present at the Charles River Cell & Gene Therapy Summit at 2:00 p.m. PT, Tuesday, March 19, 2024, in South San Francisco, Calif.

Epic Bio today announced that Amber Salzman, Ph.D., chief executive officer, will present at the BMO Fall Private Company Showcase being held Thursday, October 12, 2023, New York, NY.

Epic Bio, a leading epigenetic editing company that plans to have its FSHD program enter the clinic this year, today announced the acceptance of six abstracts, three oral presentations, and three poster presentations at the upcoming Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), taking place May 7-11, 2024, in Baltimore, Maryland.

Epic Bio announced a presentation at the upcoming CRISPR2.0 conference being held November 28-30, 2023, at the Hilton Boston Back Bay, Boston Massachusetts.

Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, announced that the management will participate in an upcoming investor conference.

Adaptive Biotechnologies Corporation today announced that clonoSEQ ® is now available to health care providers as a fully integrated test in Aura, Epic’s specialty diagnostics suite.